Cargando…

Does persistence to methotrexate treatment in early rheumatoid arthritis have a familial component?

OBJECTIVES: To assess whether persistence to treatment with methotrexate (MTX) in early rheumatoid arthritis (RA) is shared among first-degree relatives with RA and to estimate any underlying heritability. METHODS: First-degree relative pairs diagnosed with RA 1999–2018 and starting MTX (in monother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sysojev, Anton Öberg, Frisell, Thomas, Delcoigne, Bénédicte, Saevarsdottir, Saedis, Askling, Johan, Westerlind, Helga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356456/ https://www.ncbi.nlm.nih.gov/pubmed/35933427 http://dx.doi.org/10.1186/s13075-022-02873-z

Ejemplares similares

Comorbidities and treatment patterns in early rheumatoid arthritis: a nationwide Swedish study
por: Tidblad, Liselotte, et al.
Publicado: (2022)

Does autoimmune thyroid disease affects rheumatoid arthritis disease activity or response to methotrexate?
por: Waldenlind, Kristin, et al.
Publicado: (2020)

Siblings of patients with rheumatoid arthritis have an increased mortality rate: a Swedish cohort study
por: Westerlind, Helga, et al.
Publicado: (2020)

What Is the Persistence to Methotrexate in Rheumatoid Arthritis, and Does Machine Learning Outperform Hypothesis‐Based Approaches to Its Prediction?
por: Westerlind, Helga, et al.
Publicado: (2021)

Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data
por: Barbulescu, Andrei, et al.
Publicado: (2022)

Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study
por: Barbulescu, Andrei, et al.
Publicado: (2020)

Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application
por: Barbulescu, Andrei, et al.
Publicado: (2023)

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
por: Westerlind, Helga, et al.
Publicado: (2023)

A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study
por: Jiang, Xia, et al.
Publicado: (2016)

Risk of Thyroxine-Treated Autoimmune Thyroid Disease Associated With Disease Onset in Patients With Rheumatoid Arthritis
por: Waldenlind, Kristin, et al.
Publicado: (2018)

Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis
por: Bower, Hannah, et al.
Publicado: (2023)

Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
por: Molander, Viktor, et al.
Publicado: (2023)

Is tea consumption associated with reduction of risk of rheumatoid arthritis? A Swedish case-control study
por: Westerlind, Helga, et al.
Publicado: (2021)

Remaining Pain in Early Rheumatoid Arthritis Patients Treated With Methotrexate
por: Altawil, Reem, et al.
Publicado: (2016)

Sleep problems in rheumatoid arthritis over 12 years from diagnosis: results from the Swedish EIRA study
por: Lyne, Lauren, et al.
Publicado: (2022)

The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis
por: Westerlind, Helga, et al.
Publicado: (2022)

Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up
por: Manivel, Vivek Anand, et al.
Publicado: (2017)

Occupational exposure to asbestos and silica and risk of developing rheumatoid arthritis: findings from a Swedish population-based case-control study
por: Ilar, Anna, et al.
Publicado: (2019)

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
por: Frisell, Thomas, et al.
Publicado: (2023)

Allergic conditions and risk of rheumatoid arthritis: a Swedish case–control study
por: Kronzer, Vanessa L, et al.
Publicado: (2022)

A Multi‐Biomarker Disease Activity Score and the Choice of Second‐Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure
por: Hambardzumyan, Karen, et al.
Publicado: (2017)

Risk of Psychiatric Disorders in Juvenile Idiopathic Arthritis: Population‐ and Sibling‐Controlled Cohort and Cross‐Sectional Analyses
por: Delcoigne, Bénédicte, et al.
Publicado: (2023)

Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies
por: Horne, AnnaCarin, et al.
Publicado: (2019)

Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
por: Delcoigne, Bénédicte, et al.
Publicado: (2022)

Correction to: Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
por: Delcoigne, Bénédicte, et al.
Publicado: (2022)

Neither low social support nor low decision latitude at work is associated with disease remission among patients with rheumatoid arthritis: results from the Swedish EIRA study
por: Hedenstierna, Louise, et al.
Publicado: (2022)

Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study
por: Lindström, Ulf, et al.
Publicado: (2023)

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
por: Chatzidionysiou, Katerina, et al.
Publicado: (2020)

Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate
por: Hensvold, Aase Haj, et al.
Publicado: (2015)

Molecular signature of methotrexate response among rheumatoid arthritis patients
por: Brynedal, Boel, et al.
Publicado: (2023)

Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
por: Huss, Viking, et al.
Publicado: (2023)

Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice
por: Huss, Viking, et al.
Publicado: (2021)

Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
por: Di Giuseppe, Daniela, et al.
Publicado: (2021)

Dietary Intake of Polyunsaturated Fatty Acids and Pain in Spite of Inflammatory Control Among Methotrexate‐Treated Early Rheumatoid Arthritis Patients
por: Lourdudoss, Cecilia, et al.
Publicado: (2018)

Oral contraceptives, breastfeeding and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study
por: Orellana, Cecilia, et al.
Publicado: (2017)

Mannan Binding Lectin (MBL) genotypes coding for high MBL serum levels are associated with rheumatoid factor negative rheumatoid arthritis in never smokers
por: Saevarsdottir, Saedis, et al.
Publicado: (2011)

Methotrexate: who would have predicted its importance in rheumatoid arthritis?
por: Weinblatt, Michael E.
Publicado: (2018)

Postmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the Swedish EIRA population-based case-control study
por: Orellana, Cecilia, et al.
Publicado: (2015)

Etanercept‐Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis
por: Bonafede, Machaon, et al.
Publicado: (2015)

Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis
por: Salem, Heba F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b9tovadcou5qq7rvm28dl0s5bu